JP2014516027A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014516027A5 JP2014516027A5 JP2014509823A JP2014509823A JP2014516027A5 JP 2014516027 A5 JP2014516027 A5 JP 2014516027A5 JP 2014509823 A JP2014509823 A JP 2014509823A JP 2014509823 A JP2014509823 A JP 2014509823A JP 2014516027 A5 JP2014516027 A5 JP 2014516027A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- modification
- inhibitor
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 230000004048 modification Effects 0.000 claims 7
- 238000012986 modification Methods 0.000 claims 7
- 239000003112 inhibitor Substances 0.000 claims 5
- 108091034117 Oligonucleotide Proteins 0.000 claims 4
- 239000000074 antisense oligonucleotide Substances 0.000 claims 4
- 238000012230 antisense oligonucleotides Methods 0.000 claims 4
- 108091028684 Mir-145 Proteins 0.000 claims 3
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 239000002777 nucleoside Substances 0.000 claims 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims 1
- 229940112869 bone morphogenetic protein Drugs 0.000 claims 1
- 239000008263 liquid aerosol Substances 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 235000019645 odor Nutrition 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161484091P | 2011-05-09 | 2011-05-09 | |
| US61/484,091 | 2011-05-09 | ||
| US201261605376P | 2012-03-01 | 2012-03-01 | |
| US61/605,376 | 2012-03-01 | ||
| PCT/GB2012/051018 WO2012153135A1 (en) | 2011-05-09 | 2012-05-09 | Methods of modulating micrornas in the treatment of pulmonary arterial hypertension |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014516027A JP2014516027A (ja) | 2014-07-07 |
| JP2014516027A5 true JP2014516027A5 (enExample) | 2015-06-11 |
| JP6049700B2 JP6049700B2 (ja) | 2016-12-21 |
Family
ID=46178572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014509823A Expired - Fee Related JP6049700B2 (ja) | 2011-05-09 | 2012-05-09 | 肺動脈高血圧の治療におけるｍｉｃｒｏＲＮＡの調節方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9267134B2 (enExample) |
| EP (1) | EP2707485B1 (enExample) |
| JP (1) | JP6049700B2 (enExample) |
| KR (1) | KR20140037868A (enExample) |
| CN (1) | CN103814131A (enExample) |
| AU (1) | AU2012252165A1 (enExample) |
| BR (1) | BR112013029016A2 (enExample) |
| CA (1) | CA2835568A1 (enExample) |
| CO (1) | CO6870004A2 (enExample) |
| SG (1) | SG194901A1 (enExample) |
| WO (1) | WO2012153135A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2970968B1 (en) | 2013-03-15 | 2018-01-10 | Miragen Therapeutics, Inc. | Bridged bicyclic nucleosides |
| US9752143B2 (en) | 2013-03-15 | 2017-09-05 | MiRagen Therapeutics, Inc. | Locked nucleic acid inhibitor of miR-145 and uses thereof |
| WO2015082896A1 (en) * | 2013-12-02 | 2015-06-11 | The University Court Of The University Of Glasgow | Materials and methods for treatment of pulmonary arterial hypertension |
| CA2956256A1 (en) * | 2014-08-01 | 2016-02-04 | The Brigham And Women's Hospital, Inc. | Methods and compositions relating to treatment of pulmonary arterial hypertension |
| BR112017014914B1 (pt) * | 2015-01-13 | 2023-11-14 | Vivus, Inc | Uso de uma combinação de tacrolimus e um segundo agente ativo eficaz no tratamento ou prevenção da hipertensão pulmonar |
| CN110088278B (zh) * | 2016-10-31 | 2023-08-11 | e-NA生物科技公司 | 双链核酸分子及其用途 |
| CN115175685B (zh) * | 2019-12-09 | 2024-12-13 | 艾姆皮瑞克公司 | 用于治疗血管生成素样4(angptl4)相关疾病的寡核苷酸 |
| JP2024504679A (ja) * | 2021-01-18 | 2024-02-01 | リジェン イノファーム インコーポレイテッド | ｍｉＲ１４５阻害剤を有効成分として含む心筋梗塞の治療用組成物 |
| CN113332306A (zh) * | 2021-04-28 | 2021-09-03 | 武汉华纪元生物技术开发有限公司 | 用于治疗肺动脉高血压的microRNA-30a抑制剂及其应用 |
| GB202215974D0 (en) * | 2022-10-28 | 2022-12-14 | Imperial College Innovations Ltd | Microrna panels for pulmonary hypertension |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6060451A (en) | 1990-06-15 | 2000-05-09 | The National Research Council Of Canada | Thrombin inhibitors based on the amino acid sequence of hirudin |
| WO1995003843A1 (en) | 1993-07-30 | 1995-02-09 | The Regents Of The University Of California | Endocardial infusion catheter |
| GB9525620D0 (en) | 1995-12-15 | 1996-02-14 | Glaxo Group Ltd | Chemical compounds |
| SE9600216D0 (sv) | 1996-01-18 | 1996-01-18 | Hans Arne Hansson | Styrning av läkningsprocesser |
| ATE211741T1 (de) | 1996-05-31 | 2002-01-15 | C & C Res Lab | Aromatische amidinderivate als selektive thrombininhibitoren |
| US5985833A (en) | 1996-09-17 | 1999-11-16 | Wisconsin Alumni Research Foundation | Thrombin inhibitor |
| US6416510B1 (en) | 1997-03-13 | 2002-07-09 | Biocardia, Inc. | Drug delivery catheters that attach to tissue and methods for their use |
| US6147109A (en) | 1997-10-14 | 2000-11-14 | The General Hospital Corporation | Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors |
| US6749617B1 (en) | 1997-11-04 | 2004-06-15 | Scimed Life Systems, Inc. | Catheter and implants for the delivery of therapeutic agents to tissues |
| SI20474A (sl) | 1998-05-26 | 2001-08-31 | Icn Pharmaceuticals, Inc. | Novi nukleozidi, ki imajo bicikličen sladkorni del |
| EP1117398A2 (en) | 1998-09-28 | 2001-07-25 | Merck & Co., Inc. | A method for treating inflammatory diseases by administering a thrombin inhibitor |
| US6838283B2 (en) | 1998-09-29 | 2005-01-04 | Isis Pharmaceuticals Inc. | Antisense modulation of survivin expression |
| US6693187B1 (en) | 2000-10-17 | 2004-02-17 | Lievre Cornu Llc | Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge |
| EP1648914A4 (en) * | 2003-07-31 | 2009-12-16 | Regulus Therapeutics Inc | OLIGOMERIC COMPOUNDS AND COMPOSITIONS USEFUL FOR MODULATING SMALL NON-CODING RNA |
| US20070203445A1 (en) | 2004-02-26 | 2007-08-30 | V-Kardia Pty Ltd | Isolating cardiac circulation |
| BRPI0508073A (pt) | 2004-02-26 | 2007-07-17 | Kardia Pty Ltd V | método e aparelho para isolar substancialmente circulação cardìaca da circulação sistêmica aparelho para perfundir o coração com um agente terapêutico, cateter de obstrução para obstruir fluxo entre um vaso principal e um ou mais vasos ramificados, método para administrar um agente terapêutico ao coração e estrutura de suporte percutaneamente administrável para manter patência do sinus coronário |
| US7722596B2 (en) | 2004-02-26 | 2010-05-25 | Osprey Medical, Inc. | Regional cardiac tissue treatment |
| WO2006089340A2 (en) | 2005-02-23 | 2006-08-31 | V-Kardia Pty Ltd | Polynucleotide delivery to cardiac tissue |
| CN101448942B (zh) | 2005-12-12 | 2014-04-23 | 北卡罗来纳大学查珀尔希尔分校 | 调节肌细胞增殖和分化的microrna |
| WO2009121031A1 (en) | 2008-03-27 | 2009-10-01 | Vascular Biosciences, Inc. | Methods of novel therapeutic candidate identification through gene expression analysis in vascular-related diseases |
| US8735568B2 (en) | 2009-03-09 | 2014-05-27 | The J. David Gladstone Institutes | Methods of modulating smooth muscle cell proliferation and differentiation |
| CN101843632B (zh) * | 2009-03-24 | 2012-07-04 | 复旦大学附属华山医院 | miR-145在制备治疗炎症药物中的应用 |
| SG176716A1 (en) * | 2009-06-08 | 2012-01-30 | Miragen Therapeutics | CHEMICAL MODIFICATION MOTIFS FOR miRNA INHIBITORS AND MIMETICS |
| US20130005658A1 (en) * | 2009-12-15 | 2013-01-03 | Board Of Regents, The University Of Texas System | Micro-rna regulation in ischemia and ischemia-reperfusion injury |
| CN102382824A (zh) * | 2010-09-01 | 2012-03-21 | 中国科学院上海药物研究所 | 人miR-145反义核酸及其应用 |
-
2012
- 2012-05-09 CN CN201280034183.8A patent/CN103814131A/zh active Pending
- 2012-05-09 KR KR1020137032530A patent/KR20140037868A/ko not_active Withdrawn
- 2012-05-09 SG SG2013083480A patent/SG194901A1/en unknown
- 2012-05-09 WO PCT/GB2012/051018 patent/WO2012153135A1/en not_active Ceased
- 2012-05-09 AU AU2012252165A patent/AU2012252165A1/en not_active Abandoned
- 2012-05-09 CA CA2835568A patent/CA2835568A1/en not_active Abandoned
- 2012-05-09 JP JP2014509823A patent/JP6049700B2/ja not_active Expired - Fee Related
- 2012-05-09 EP EP12724369.9A patent/EP2707485B1/en not_active Not-in-force
- 2012-05-09 US US14/116,724 patent/US9267134B2/en not_active Expired - Fee Related
- 2012-05-09 BR BR112013029016A patent/BR112013029016A2/pt not_active IP Right Cessation
-
2013
- 2013-11-14 CO CO13268130A patent/CO6870004A2/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014516027A5 (enExample) | ||
| JP2016116520A5 (enExample) | ||
| HRP20201200T1 (hr) | OLIGONUKLEOTIDNI SPOJEVI ZA CILJANJE HUNTINGTIN mRNK | |
| MX2024005653A (es) | Agentes de acido ribonucleico (arn) de cadena doble modificados. | |
| JP2012516856A5 (enExample) | ||
| JP2016520310A5 (enExample) | ||
| JP2016513976A5 (enExample) | ||
| JP2016522674A5 (enExample) | ||
| HRP20241138T1 (hr) | Oligonukleotidi za induciranje ekspresije očinskog ube3a | |
| JP2017505623A5 (enExample) | ||
| JP2018530530A5 (enExample) | ||
| JP2015518712A5 (enExample) | ||
| JP2014527401A5 (enExample) | ||
| JP2015518710A5 (enExample) | ||
| JP2009532392A5 (enExample) | ||
| JP2015502365A5 (enExample) | ||
| JP2018525357A5 (enExample) | ||
| JP2014511686A5 (enExample) | ||
| JP2012510297A5 (enExample) | ||
| JP2016521556A5 (enExample) | ||
| JP2015519057A5 (enExample) | ||
| HRP20160336T1 (hr) | Protusmjerna nukleinska kiselina | |
| JP2015511821A5 (enExample) | ||
| JP2015523855A5 (enExample) | ||
| CA2921459A1 (en) | Oligonucleotides targeting euchromatin regions of genes |